How To Build A Cell Therapy CMC Roadmap

By Bruce Thompson, Ph.D., President and Chief Technology Officer and Roger Herr, Ph.D., Director, Analytical Development

Bringing a living cell therapy to market demands a proactive approach to Chemistry, Manufacturing, and Controls (CMC). Unlike traditional small molecules, cellular products possess inherent biological variability that introduces unique regulatory risks and operational hurdles early in development. Establishing a rigorous, phase-appropriate CMC roadmap is essential to balance early-stage flexibility with the strict compliance required for commercialization.

Key focus areas include robust assay development to ensure identity and potency, detailed characterization of raw materials, and scalable manufacturing workflows. Addressing these technical pillars early mitigates the risk of costly clinical holds and unexpected delays during regulatory reviews. Developing a structured framework allows therapy developers to align technical milestones with clinical timelines seamlessly. Review the comprehensive guide to build a robust, data-driven strategy that safeguards your pipeline and accelerates commercial readiness.